Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
about
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaUsing gene therapy to manipulate the immune system in the fight against B-cell leukemiasBCL6 modulation of acute lymphoblastic leukemia response to chemotherapyEfficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemiaTreating adults with acute lymphocytic leukemia: new pharmacotherapy options.Interpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing ProgramManagement and treatment of relapsed or refractory Ph(-) B-precursor ALL: a web-based, double-blind survey of EU clinicians.High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007.Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United KingdomLong-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia.The myth of the second remission of acute leukemia in the adult.Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemiaAcute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylationAllogeneic stem cell transplant for adult Philadelphia chromosome-negative acute lymphoblastic leukemia.Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available?Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.CAR T-cells merge into the fast lane of cancer care.Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective.Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.A case of me: clinical cancer sequencing and the future of precision medicine.Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia.BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.Continuing challenges and current issues in acute lymphoblastic leukemia.Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy.Apoptotic induction in B-cell acute lymphoblastic leukemia cell lines treated with a protein kinase Cβ inhibitor.
P2860
Q26744280-1D4531DD-B615-461F-8C9D-050339DE4F05Q27011297-3C6A7F42-38DA-4F47-A6E4-426C1A2A747DQ28829626-4699001E-56FA-4BB1-9833-D63515A04ECFQ29617590-545CE6C9-B867-420A-9BC3-6791E19FCA59Q30243925-CEAD3432-8B0B-479F-8CD8-81C3E09AF9CEQ30884173-A507920C-C83C-4394-AE78-01951011A4C0Q33822004-74F681CA-3DAB-4448-B1EE-360EC72D5126Q34543909-61A11B9A-B38C-498C-BC3F-FD574E4014E7Q35820095-7E6FC658-723C-4C10-8CEE-65F4280FEED0Q36216252-47746F86-09FA-4001-9EA8-940B40180BDCQ36287149-0641D300-8D16-4599-AD97-7EA1732E977EQ36350443-10A0B435-4899-4939-B0A2-A9CE73758B5CQ36529403-74908E2B-63ED-4BCB-9F64-662BF5E678B7Q36619678-9042B80F-E696-401C-99B1-AB1BC25A4D1BQ37325019-F58CB23C-3A6F-42B2-8CE4-8B531397D7E4Q37575938-2685BBB9-448C-4FA3-9AC1-98E5E9BFC635Q37675273-0E97E984-FE38-4009-95B4-06FA6BD0DFD7Q37676956-99614D45-6A5A-4525-9157-563066F84B92Q37919867-10518BB6-EA52-4649-8C0F-707EA065A91DQ38002447-1AF79046-2852-4DBF-867D-4457B36BBD12Q38087853-D2472F05-0D2F-405B-88F1-6E8B8280E06DQ38087930-B3FE0DD4-F039-4F67-8A7E-0339C0908DF7Q38226402-CB067DB4-496F-4D58-AD28-3446399B29ECQ38434000-0E865F61-3E9C-4583-A3B6-C110DA8A56DBQ38515225-66400904-6ABE-4630-B707-1DFF0ABC7B13Q38610250-4151F836-3252-4924-8995-CF7DF065016BQ38635027-9176A1B8-4767-4C85-AFF4-723820A11D43Q38639698-0E376E84-9BC6-422A-A1D7-3F1C7D887886Q38717851-14173247-E6AF-49EF-A1CF-2AB374C5AEECQ38722012-3A858539-5245-4C92-ADB0-CB7435615CFEQ38838682-3323214B-D982-4490-8A84-0B5934704D50Q38840247-CB29A629-E13D-466E-85A3-125E48EAF99BQ38856091-1BED3197-FC55-4797-A1A5-8E85A58EC644Q38871220-E1E62455-F94E-4CFD-A191-E9F8CD5F6030Q38872343-A6806019-D6DC-4DCB-BCA8-D76927B31D43Q39122060-AEA43F7B-CEB6-41A0-B198-8430331498C0Q39366299-55D9CCC0-877F-4EBD-968E-2621F9A74F38Q39401736-927EE57D-9CAB-4E40-83F7-D11116BACC1AQ39418546-105B3ADD-73F6-49B3-91AB-2341021B8259Q39601989-88A2EADB-3EA8-4554-8F47-BF1E1422A0F8
P2860
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@ast
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@en
type
label
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@ast
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@en
prefLabel
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@ast
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@en
P2093
P2860
P1433
P1476
Outcome after relapse of acute ...... ls by the PETHEMA Study Group.
@en
P2093
Albert Oriol
Carlos Grande
Carlota Calvo
Concepción Bethencourt
Concepción Rivas
Eloy del Potro
Evarist Feliu
Federico Moscardó
Inmaculada Heras
Javier Bueno
P2860
P304
P356
10.3324/HAEMATOL.2009.014274
P577
2010-02-09T00:00:00Z